Literature DB >> 19709661

Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables.

A Tuttolomondo1, D Di Raimondo, R Di Sciacca, A Casuccio, G Bivona, C Bellia, L Barreca, A Serio, G D'Aguanno, M Ciaccio, G Licata, A Pinto.   

Abstract

INTRODUCTION: Accumulating evidence suggests that inflammation plays an important role in the acute phase of ischemic stroke. CD40 L is a well recognized atherosclerotic inflammatory marker, whereas recent evidence suggests a pro-inflammatory role of Fetuin-A. To analyze the role of an inflammatory marker such as CD40 L and of a candidate pro-inflammatory marker such as Fetuin-A in acute stroke we evaluated their serum levels in subjects with acute ischemic stroke and their possible association with other laboratory and clinical variables.
MATERIALS AND METHODS: We enrolled 107 consecutive patients with a diagnosis of acute ischemic stroke admitted to the Internal Medicine Department at the University of Palermo between November 2006 and January 2008, and 102 hospitalized control patients without a diagnosis of acute ischemic stroke.
RESULTS: Patients with acute ischemic stroke in comparison to control subjects without acute ischemic stroke had significantly higher CD40 L levels and Fetuin-A serum levels. No significant differences in plasma CD40 L or Fetuin-A levels among different TOAST groups were detected. At intragroup (intra-TOAST-subtype) correlation analysis, among subjects classified as lacunar, CD40 L plasma levels were positively correlated with LDL-cholesterol and with diabetes, whereas Fetuin-A was significantly (positively) correlated with hypertension and white blood cell count. Among subjects with LAAS subtype, CD40 L levels were positively correlated with triglyceride plasma levels and Fetuin-A, whereas Fetuin-A levels were positively correlated with LDL-cholesterol. DISCUSSION: Our findings suggest a pro-inflammatory role of Fetuin-A and CD40 L in acute stroke setting. Whether this role should be construed as direct or as a simple expression of a general inflammatory activation will be up to future studies to clarify. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709661     DOI: 10.1016/j.atherosclerosis.2009.07.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats.

Authors:  Haichao Wang; Wei Li; Shu Zhu; Jianhua Li; Jason D'Amore; Mary F Ward; Huan Yang; Rongqian Wu; Willi Jahnen-Dechent; Kevin J Tracey; Ping Wang; Andrew E Sama
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-02       Impact factor: 6.200

2.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

3.  Inhibition of Peripheral TNF-α and Downregulation of Microglial Activation by Alpha-Lipoic Acid and Etanercept Protect Rat Brain Against Ischemic Stroke.

Authors:  Ming-Hsiu Wu; Chao-Ching Huang; Chung-Ching Chio; Kuen-Jer Tsai; Ching-Ping Chang; Nan-Kai Lin; Mao-Tsun Lin
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 4.  Anti-inflammatory role of fetuin-A in injury and infection.

Authors:  H Wang; A E Sama
Journal:  Curr Mol Med       Date:  2012-06       Impact factor: 2.222

5.  AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity?

Authors:  X Julia Xu; Rudy J Valentine; Neil B Ruderman
Journal:  Curr Obes Rep       Date:  2014-06-01

6.  Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease.

Authors:  David Peter Lorant; Milan Grujicic; Clemens Hoebaus; Johanna-Maria Brix; Florian Hoellerl; Guntram Schernthaner; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  Diabetes Care       Date:  2010-10-07       Impact factor: 19.112

7.  A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation.

Authors:  Wei Li; Shu Zhu; Jianhua Li; Yan Huang; Rongrong Zhou; Xuegong Fan; Huan Yang; Xing Gong; N Tony Eissa; Willi Jahnen-Dechent; Ping Wang; Kevin J Tracey; Andrew E Sama; Haichao Wang
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

8.  Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients.

Authors:  Hung-Yuan Chen; Chien-Chu Lin; Yen-Lin Chiu; Shih-Ping Hsu; Mei-Fen Pai; Ju-Yeh Yang; Yu-Sen Peng
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.

Authors:  Gurkan Celebi; Halil Genc; Hasan Gurel; Erdim Sertoglu; Muammer Kara; Serkan Tapan; Cengizhan Acikel; Yildirim Karslioglu; Cemal Nuri Ercin; Teoman Dogru
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

10.  Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction.

Authors:  Leonardo Lorente; María M Martín; Agustín F González-Rivero; Luis Ramos; Mónica Argueso; Juan J Cáceres; Jordi Solé-Violán; Alejandro Jiménez; Juan M Borreguero-León
Journal:  Int J Mol Sci       Date:  2015-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.